Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy …
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy Read More